Cargando…

A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease

Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system (CNS) leading to mental deterioration and devastation, and eventually a fatal outcome. AD affects mostly the elderly. AD is frequently accompanied by hypercholesterolemia, hypertension, atheroscle...

Descripción completa

Detalles Bibliográficos
Autores principales: Maciejewska, Karolina, Czarnecka, Kamila, Szymański, Paweł
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599320/
https://www.ncbi.nlm.nih.gov/pubmed/34121170
http://dx.doi.org/10.1007/s43440-021-00293-5
_version_ 1784600922845872128
author Maciejewska, Karolina
Czarnecka, Kamila
Szymański, Paweł
author_facet Maciejewska, Karolina
Czarnecka, Kamila
Szymański, Paweł
author_sort Maciejewska, Karolina
collection PubMed
description Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system (CNS) leading to mental deterioration and devastation, and eventually a fatal outcome. AD affects mostly the elderly. AD is frequently accompanied by hypercholesterolemia, hypertension, atherosclerosis, and diabetes mellitus, and these are significant risk factors of AD. Other conditions triggered by the progression of AD include psychosis, sleep disorders, epilepsy, and depression. One important comorbidity is Down’s syndrome, which directly contributes to the severity and rapid progression of AD. The development of new therapeutic strategies for AD includes the repurposing of drugs currently used for the treatment of comorbidities. A better understanding of the influence of comorbidities on the pathogenesis of AD, and the medications used in its treatment, might allow better control of disease progression, and more effective pharmacotherapy. GRAPHIC ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-8599320
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-85993202021-11-24 A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease Maciejewska, Karolina Czarnecka, Kamila Szymański, Paweł Pharmacol Rep Review Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system (CNS) leading to mental deterioration and devastation, and eventually a fatal outcome. AD affects mostly the elderly. AD is frequently accompanied by hypercholesterolemia, hypertension, atherosclerosis, and diabetes mellitus, and these are significant risk factors of AD. Other conditions triggered by the progression of AD include psychosis, sleep disorders, epilepsy, and depression. One important comorbidity is Down’s syndrome, which directly contributes to the severity and rapid progression of AD. The development of new therapeutic strategies for AD includes the repurposing of drugs currently used for the treatment of comorbidities. A better understanding of the influence of comorbidities on the pathogenesis of AD, and the medications used in its treatment, might allow better control of disease progression, and more effective pharmacotherapy. GRAPHIC ABSTRACT: [Image: see text] Springer International Publishing 2021-06-13 2021 /pmc/articles/PMC8599320/ /pubmed/34121170 http://dx.doi.org/10.1007/s43440-021-00293-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Maciejewska, Karolina
Czarnecka, Kamila
Szymański, Paweł
A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
title A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
title_full A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
title_fullStr A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
title_full_unstemmed A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
title_short A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
title_sort review of the mechanisms underlying selected comorbidities in alzheimer’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599320/
https://www.ncbi.nlm.nih.gov/pubmed/34121170
http://dx.doi.org/10.1007/s43440-021-00293-5
work_keys_str_mv AT maciejewskakarolina areviewofthemechanismsunderlyingselectedcomorbiditiesinalzheimersdisease
AT czarneckakamila areviewofthemechanismsunderlyingselectedcomorbiditiesinalzheimersdisease
AT szymanskipaweł areviewofthemechanismsunderlyingselectedcomorbiditiesinalzheimersdisease
AT maciejewskakarolina reviewofthemechanismsunderlyingselectedcomorbiditiesinalzheimersdisease
AT czarneckakamila reviewofthemechanismsunderlyingselectedcomorbiditiesinalzheimersdisease
AT szymanskipaweł reviewofthemechanismsunderlyingselectedcomorbiditiesinalzheimersdisease